Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MacroGenics, Inc.

http://www.macrogenics.com/

Latest From MacroGenics, Inc.

Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO

Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors

Companies Commercial

Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza

While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.

Clinical Trials Cancer

10 US Approval Decisions To Look Out For In Q3

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Approvals Companies

Asia Deal Watch: Zhaoke, PanOptica Finalize Neovascular Eye Disease Alliance

Plus deals involving Zai Lab/MacroGenics, Ono/Rafael Pharmaceuticals, Beijing Podconley/Norgine, Nuance/Verona and BeiGene/Shoreline.

Deal Watch Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Raven Biotechnologies
UsernamePublicRestriction

Register